blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4499838

EP4499838 - ENGINEERED GENE EFFECTORS, COMPOSITIONS, AND METHODS OF USE THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  03.01.2025
Database last updated on 14.03.2026
FormerThe international publication has been made
Status updated on  29.09.2023
Most recent event   Tooltip07.03.2026New entry: Renewal fee paid 
Applicant(s)For all designated states
Epicrispr Biotechnologies, Inc.
7000 Shoreline Court, Suite 100
South San Francisco, CA 94080 / US
[2025/06]
Inventor(s)01 / CAROSSO, Giovanni
South San Francisco, California 94080 / US
02 / QI, Lei S.
South San Francisco, California 94080 / US
03 / HART, Daniel O.
South San Francisco, California 94080 / US
04 / YEO, Robin W.
South San Francisco, California 94080 / US
05 / DALEY, Timothy
South San Francisco, California 94080 / US
06 / JAWAID, Muhammad Zaki
South San Francisco, California 94080 / US
 [2025/06]
Representative(s)Plougmann Vingtoft a/s
Strandvejen 70
2900 Hellerup / DK
[2025/06]
Application number, filing date23775904.823.03.2023
[2025/06]
WO2023US64887
Priority number, dateUS202263323248P24.03.2022         Original published format: US 202263323248 P
US202263381255P27.10.2022         Original published format: US 202263381255 P
US202363489873P13.03.2023         Original published format: US 202363489873 P
[2025/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2023183893
Date:28.09.2023
Language:EN
[2023/39]
Type: A1 Application with search report 
No.:EP4499838
Date:05.02.2025
Language:EN
The application published by WIPO in one of the EPO official languages on 28.09.2023 takes the place of the publication of the European patent application.
[2025/06]
Search report(s)International search report - published on:AU28.09.2023
(Supplementary) European search report - dispatched on:EP19.02.2026
ClassificationIPC:C12N15/63, C07K14/005, C07K14/47, C12N9/22, C12N15/113
[2025/06]
CPC:
C07K14/005 (EP,AU); C12N15/63 (AU); C07K14/4705 (AU,US);
C12N15/113 (EP,AU); C12N15/635 (AU); C12N9/22 (EP,AU);
C12N9/226 (US); C07K2319/00 (EP); C07K2319/70 (EP);
C07K2319/71 (EP); C07K2319/85 (AU); C12N2310/20 (EP,AU);
C12N2710/16222 (AU); C12N2710/16422 (EP,AU); C12N2710/16622 (AU) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   ME,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2025/06]
TitleGerman:MANIPULIERTE GENEFFEKTOREN, ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON[2025/06]
English:ENGINEERED GENE EFFECTORS, COMPOSITIONS, AND METHODS OF USE THEREOF[2025/06]
French:EFFECTEURS GÉNIQUES MODIFIÉS, COMPOSITIONS ET LEURS PROCÉDÉS D'UTILISATION[2025/06]
Entry into regional phase11.10.2024National basic fee paid 
11.10.2024Search fee paid 
11.10.2024Designation fee(s) paid 
11.10.2024Examination fee paid 
Examination procedure11.10.2024Examination requested  [2025/06]
30.04.2025Amendment by applicant (claims and/or description)
Fees paidRenewal fee
09.05.2025Renewal fee patent year 03
06.03.2026Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
31.03.202503   M06   Fee paid on   09.05.2025
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[PX] WO2023004338  (EPICRISPR BIOTECHNOLOGIES INC et al.) [PX] 1-15 * claim 20 * * sequence 23639 *
 [A]   LUKE A. GILBERT ET AL: "CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes", CELL, vol. 154, no. 2, 1 July 2013 (2013-07-01), pages 442 - S5, XP055167546, ISSN: 0092-8674, DOI: 10.1016/j.cell.2013.06.044 [A] 1-15 * abstract * * page 443, column r, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/j.cell.2013.06.044
 [A]   JESSE G. ZALATAN ET AL: "Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds", CELL, vol. 160, no. 1-2, 1 January 2015 (2015-01-01), Amsterdam NL, pages 339 - 350, XP055278878, ISSN: 0092-8674, DOI: 10.1016/j.cell.2014.11.052 [A] 1-15 * abstract * * figure 1 * * figure 2A *

DOI:   http://dx.doi.org/10.1016/j.cell.2014.11.052
 [A]   ALEJANDRO CHAVEZ ET AL: "Highly efficient Cas9-mediated transcriptional programming", NATURE METHODS, vol. 12, no. 4, 1 April 2015 (2015-04-01), New York, pages 326 - 328, XP055371318, ISSN: 1548-7091, DOI: 10.1038/nmeth.3312 [A] 1-15 * abstract * * figure 1 *

DOI:   http://dx.doi.org/10.1038/nmeth.3312
 [A]   ISAAC B HILTON ET AL: "Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers", NATURE BIOTECHNOLOGY, vol. 33, no. 5, 6 April 2015 (2015-04-06), New York, pages 510 - 517, XP055327077, ISSN: 1087-0156, DOI: 10.1038/nbt.3199 [A] 1-15

DOI:   http://dx.doi.org/10.1038/nbt.3199
International search[P,X] WO2023004338  (EPICRISPR BIOTECHNOLOGIES INC et al.) [P,X] 1-37, 40-52 * [583-585], [595], Fig. 24A, Fig. 24B, Fig. 28; SEQ ID NOs: 23631, 23639 *
 [X]   KOCH SANDRA, DAMAS MODESTER, FREISE ANIKA, HAGE ELIAS, DHINGRA AKSHAY, RCKERT JESSICA, GALLO ANTONIO, KREMMER ELISABETH, TEGGE WE: "Kaposis sarcoma-associated herpesvirus vIRF2 protein utilizes an IFN-dependent pathway to regulate viral early gene expression", PLOS PATHOGENS, vol. 15, no. 5, 6 May 2019 (2019-05-06), pages e1007743, XP093096396, DOI: 10.1371/journal.ppat.1007743 [X] 28, 29, 35-37, 42-44, 48-51 * Abstract; "Domains of vIRF2 required for the restriction of KSHV early lytic protein expression in endothelial cells", last paragraph; Fig 6a *

DOI:   http://dx.doi.org/10.1371/journal.ppat.1007743
 [X]   XIANG QIWANG, JU HYUNWOO, NICHOLAS JOHN: "USP7-Dependent Regulation of TRAF Activation and Signaling by a Viral Interferon Regulatory Factor Homologue", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 94, no. 2, 6 January 2020 (2020-01-06), US , XP093096399, ISSN: 0022-538X, DOI: 10.1128/JVI.01553-19 [X] 28, 29, 35-37, 42-44, 48, 49 * ; Fig. 2A *

DOI:   http://dx.doi.org/10.1128/JVI.01553-19
 [A]   HU HAIDAI, DONG JIAZHEN, LIANG DEGUANG, GAO ZENGQIANG, BAI LEI, SUN RUI, HU HAO, ZHANG HENG, DONG YUHUI, LAN KE: "Genome-Wide Mapping of the Binding Sites and Structural Analysis of Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 2 Reveal that It Is a DNA-Binding Transcription Factor", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 90, no. 3, 1 February 2016 (2016-02-01), US , pages 1158 - 1168, XP093096403, ISSN: 0022-538X, DOI: 10.1128/JVI.01392-15 [A] 0 * Abstract; Materials and Methods; Table 1 *

DOI:   http://dx.doi.org/10.1128/JVI.01392-15
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.